tremelimumab
Showing 26 - 50 of 105
Advanced Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Tremelimumab)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
-
La Jolla, California
- +46 more
May 22, 2023
Colorectal Cancer Metastatic Trial in United States (durvalumab, Tremelimumab)
Completed
- Colorectal Cancer Metastatic
- durvalumab
- Tremelimumab
-
Duarte, California
- +17 more
Nov 8, 2022
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma Trial in United States (Durvalumab, Tremelimumab)
Active, not recruiting
- Germ Cell Tumor
- +5 more
- Durvalumab
- Tremelimumab
-
Basking Ridge, New Jersey
- +6 more
May 2, 2022
Bladder Cancer, High-Risk Cancer, Tremelimumab Trial in Vancouver (Tremelimumab)
Recruiting
- Bladder Cancer
- +4 more
- Tremelimumab
-
Vancouver, British Columbia, CanadaVancouver General Hospital
Nov 3, 2021
Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension Trial in Cincinnati (Durvalumab, Tremelimumab, Liver Transplant)
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Cincinnati, OhioUniversity of Cincinnati
Dec 8, 2021
Infiltrating Bladder Urothelial Carcinoma Trial in France (Durvalumab, Tremelimumab, MVAC Protocol)
Recruiting
- Infiltrating Bladder Urothelial Carcinoma
- Durvalumab
- +2 more
-
Paris, Ile De France, France
- +14 more
Apr 21, 2022
Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Tremelimumab, Yttrium-90 radioembolisation)
Recruiting
- Hepatocellular Carcinoma
- Durvalumab
- +2 more
-
Hong Kong, Hong KongDepartment of Clinical Oncology, Queen Mary Hospital
Apr 10, 2023
Metastatic or Locally Advanced NSCLC Trial in Ramat Gan (Durvalumab, Tremelimumab, Low dose irradiation)
Recruiting
- Metastatic or Locally Advanced NSCLC
- Durvalumab
- +2 more
-
Ramat Gan, IsraelSheba Medical Centre
Jan 9, 2022
Mesothelioma, Malignant Trial in Toronto (Cyclophosphamide, Tremelimumab, Durvalumab)
Recruiting
- Mesothelioma, Malignant
- Cyclophosphamide
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
May 13, 2022
Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)
Withdrawn
- Squamous Non-small Cell Lung Cancer
- Non-Squamous Non-small Cell Lung Cancer
- Durvalumab
- Tremelimumab
- (no location specified)
Dec 17, 2021
Invasive Bladder Cancer Trial in Spain (Durvalumab, Tremelimumab, Radiotherapy)
Active, not recruiting
- Invasive Bladder Cancer
- Durvalumab
- +2 more
-
Badalona, Barcelona, Spain
- +6 more
Mar 9, 2022
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,
Recruiting
- Biliary Tract Cancer (CCA)
- +4 more
- Durvalumab
- +2 more
-
Frankfurt am Main, GermanyKrankenhaus Nordwest
Jun 23, 2022
Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)
Active, not recruiting
- Biliary Tract Neoplasms
- Durvalumab
- +3 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 26, 2021
Urothelial Carcinoma Trial in United States (Tremelimumab)
Active, not recruiting
- Urothelial Carcinoma
- Tremelimumab
-
Washington, District of Columbia
- +6 more
Feb 24, 2022
Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma Trial in London (Savolitinib, MEDI4736, Tremelimumab)
Active, not recruiting
- Renal Clear Cell Carcinoma
- Renal Papillary Cell Carcinoma
- Savolitinib
- +2 more
-
London, United KingdomThomas Powles
Aug 10, 2022
Esophageal Adenocarcinoma Trial in Cologne, München (Durvalumab 50 MG/ML, Tremelimumab)
Recruiting
- Esophageal Adenocarcinoma
- Durvalumab 50 MG/ML
- Tremelimumab
-
Cologne, Germany
- +1 more
Feb 17, 2022
Intrahepatic Cholangiocarcinoma Trial in Germany (Durvalumab, Tremelimumab)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Durvalumab
- Tremelimumab
-
Dresden, Germany
- +7 more
Apr 13, 2022
Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma Trial in Edmonton, London, Montréal (SBRT, Durvalumab,
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Metastatic Squamous Cell Carcinoma
- SBRT
- +2 more
-
Edmonton, Alberta, Canada
- +2 more
Mar 14, 2022
Solid Malignancies Trial in Canada (durvalumab, tremelimumab)
Active, not recruiting
- Solid Malignancies
- durvalumab
- tremelimumab
-
Calgary, Alberta, Canada
- +6 more
Jan 24, 2022
Prostate Cancer Trial in Canada (Durvalumab, Tremelimumab)
Active, not recruiting
- Prostate Cancer
- Durvalumab
- Tremelimumab
-
Kelowna, British Columbia, Canada
- +10 more
Mar 14, 2022
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma Trial in United States (Durvalumab, Tremelimumab, Poly ICLC)
Completed
- Head and Neck Squamous Cell Carcinoma
- +10 more
- Durvalumab
- +2 more
-
Atlanta, Georgia
- +6 more
Mar 1, 2022
Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable Trial in Hannover (Durvalumab, Gemcitabine,
Active, not recruiting
- Cholangiocarcinoma
- +3 more
- Durvalumab
- +3 more
-
Hannover, GermanyMedizinische Hochschule Hannover, Klinik für Gastroenterologie,
Oct 14, 2021
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer Trial in Spain
Recruiting
- Metastatic Thyroid Papillary Carcinoma
- +2 more
- Durvalumab
- Tremelimumab
-
L'Hospitalet de Llobregat, Barcelona, Spain
- +14 more
Feb 18, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma Trial in United
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Carboplatin
- +6 more
-
Orange, California
- +15 more
Aug 23, 2022